The Production of a Factor X Activator by a Methylcholanthrene-Induced Rat Fibrosarcoma

Summary

The association between neoplasia and thrombosis has been well documented. We have studied the production of a procoagulant which is a factor X activator in a rat fibrosarcoma model. Extracts of excised tumor were assayed in a one stage clotting assay using normal and factor deficient human plasmas. The activity was not due to tissue factor, as acceleration of clotting was observed in FVII deficient plasma. No activity was noted in FX deficient plasma. The activator was capable of cleaving ¹²⁵I-FX in the absence or presence of calcium. A radioimmunoassay (RIA) demonstrated a 5,100-fold increase in the levels of FX activation peptide after exposure to sarcoma extract. The FX activation occurs in the absence of calcium although the effect is greatly accelerated in the presence of 5 mM CaCl₂. Using a two-stage amidolytic assay, functional activation of FX by the sarcoma was demonstrated. Inhibitor studies suggest that the sarcoma-derived procoagulant is a serine protease. The methylcholanthrene-induced rat sarcoma may serve as a useful model for investigating the regulation and effects of cancer procoagulants.

• REFERENCES

• 1 Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l’Hôtel-Dieu de Paris. London, New Sydenham Society: 1865. 3 94
• 2 Sack Jr GH, Levin J, Bell WR. Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine 1977; 56: 01-37
• 3 Hoerr SO, Harper JR. On peripheral thrombophlebitis; its occurence as a presenting symptom in malignant disease of the pancreas, biliary tract or duodenum. JAMA 1957; 164: 2033-2044
• 4 Kasimis BS, Spiers AS. Thrombotic complications in patients with advanced prostatic cancer treated with chemotherapy. Lancet 1979; 1: 159
• 5 Sproul EE. Carcinoma and venous thrombosis: frequency of association of carcinoma in body or tail of pancreas with multiple venous thrombosis. Am J Cancer 1938; 34: 566-585
• 6 Francis JL. Haemostasis and cancer. Med Lab Sci 1989; 46: 331-346
• 7 Rickles R, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31
• 8 Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975; 6: 61-71
• 9 Gore JM, Appelbaum JS, Greene HL, Dexter L, Dalen JE. Occult cancer in patients with pulmonary embolism. Ann Intern Med 1982; 96: 556-566
• 10 Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauws S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-407
• 11 Pineo G, Brain MC, Gallus AS, Hirsh J, Hatton MWC, Regoeczi E. Tumors, mucus production and hypercoagulability. Ann NY Acad Sci 1974; 230: 262-270
• 12 Spar IL, Bale W, Marrack D, Dewey WC, McCardle RJ, Harper PV. ¹³¹I-labeled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials. Cancer. 1967; 20: 865-870
• 13 Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61: 46-52
• 14 Powles TJ, Easty GC, Easty DM, Neville AM. Antimetastatic effect of aspirin. Lancet 1973; 2: 100
• 15 Pollard M, Luckert PH. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981; 214: 558-559
• 16 Gastpar H. Platelet-cancer cell interaction in metastasis formation: a possible therapeutic approach to metastasis prophylaxis. J Med 1977; 8: 103-114
• 17 Hagmar B. Experimental tumour metastases and blood coagulability. Acta Pathol Microbiol Scand 1970; 211: 05-38
• 18 Kadish JL, Wenc KM, Dvorak H. Tissue factor activity of normal and neoplastic cells: quantitation and species specificity. J Natl Cancer Inst 1983; 70: 551-557
• 19 Gouault-Heilman M, Chardon E, Sultan C, Josso F. The procoagulant factor of leukaemic promyelocytes: demonstration of immunologic cross reactivity with human brain tissue factor. Br J Haematol 1975; 30: 151-158
• 20 Gordon SG, Franks JJ, Lewis B. Cancer procoagulant A: a Factor X activating procoagulant from malignant tissue. Thromb Res 1975; 6: 127-137
• 21 Francis JL, El-Baruni K, Roath OS, Taylor I. Factor X-activating activity in normal and malignant colorectal tissue. Thromb Res 1988; 52: 207-217
• 22 El-Baruni K, Taylor I, Roath S, Francis JL. Factor X-activating procoagulant in normal and malignant breast tissue. Hematol Oncol 1990; 8: 323-332
• 23 Gordon SG, Lewis BJ. Comparison of procoagulant activity in tissue culture medium from normal and transformed fibroblasts. Cancer Res 1978; 38: 2467-2472
• 24 Gordon SG, Franks JJ, Lewis BJ. Comparison of procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst 1979; 62: 773-776
• 25 Gordon S, Sloane B, Cavanaugh P, Cross B, McLaughlin R, Honn K, Chelladurai M. Purification and characterization of two procoagulants from Walker 256 carcinosarcoma tumors. Thromb Haemostas 1987; 58 (Suppl) 235
• 26 Redgrave TG, Devereux D, Deckers PJ. Hyperlipidemia in tumor-bearing rats. Biochim Biophys Acta 1984; 795: 286-292
• 27 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 28 Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of Factor X activation in humans. Blood 1989; 74: 2007-2015
• 29 Zacharski LR, Rosenstein R, Phillips PG. Concanavalin A inhibition of tissue factor (thromboplastin) activity. Blood 1974; 44: 783-787
• 30 Gasic GJ, Gasic TB, Jimenez SA. Platelet aggregating material in mouse tumor cells. Removal and regeneration. Lab Invest 1977; 36: 413-419
• 31 Pearlstein E, Ambrogio C, Gasic G, Karpatkin S. Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor, dansylarginine N-(3-ethyl-l,5-pentanediyl) amide. Cancer Res 1981; 41: 4535-4539
• 32 Bastida E, Ordinas A, Jamieson GA. Differing platelet aggregating effects by two tumor cell lines: absence of role for platelet-derived ADP. Am J Hematol 1981; 11: 367-378
• 33 Karpatkin S, Smerling A, Pearlstein E. Plasma requirement for the aggregation of rabbit platelets by an aggregating material derived from SV40-transformed 3T3 fibroblast. J Lab Clin Med 1980; 96: 994-1001
• 34 Edwards RL, Rickles R, Bobrove AM. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood 1979; 54: 359-370
• 35 Lorenzet R, Peri G, Locati D, Allavena P, Colucci M, Semeraro N, Mantovani A, Donati MB. Generation of procoagulant activity by mononuclear phagocytes: a possible mechanism contributing to blood clotting activation within malignant tissues. Blood 1983; 62: 271-273
• 36 Gralnick HR, Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia. Br J Haematol 1973; 24: 89-99
• 37 Ewan VA, Edwards RL, Rickles R. Expression of procoagulant activity in a human monocyte-like cell line. J Lab Clin Med 1983; 101: 401-410
• 38 Silberberg JM, Gordon S, Zucker S. Identification of tissue factor in two human pancreatic cancer cell lines. Cancer Res 1989; 49: 5443-5447
• 39 Khato J, Suzuki M, Sato H. Quantitative study in thromboplastin in various strains of Yoshida ascites hepatoma cells of rat. Gann 1974; 65: 289-294
• 40 Hilgard P, Whur P. Factor X-activating activity from Lewis lung carcinoma. Br J Cancer 1980; 41: 642-643
• 41 Curatolo L, Colucci M, Cambini AL, Poggi A, Morasca L, Donati MB, Semeraro N. Evidence that cells from experimental tumours can activate coagulation factor X. Br J Cancer 1979; 40: 228-233
• 42 Grignani G, Falanga A, Pacchiarini L, Allessio MG, Zucchella M, Fratino P, Donati MB. Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. Int J Cancer 1988; 42: 554-557
• 43 Cavanaugh PG, Sloane B, Honn KV. Role of the coagulation system in tumor-cell induced platelet aggregation and metastasis. Haemostasis 1988; 18: 37-46
• 44 Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558-5567
• 45 Gordon SG, Hasiba U, Cross BA, Poole MA, Falanga A. Cysteine proteinase procoagulant from amnion-chorion. Blood 1985; 66: 1261-1265
• 46 Donati MB, Gambacorti-Passerini C, Casali B, Falanga A, Vannotti P, Fossati G, Semeraro N, Gordon SG. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res 1986; 46: 6471-6474
• 47 Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood 1988; 71: 870-875
• 48 Bach R, Gentry R, Nemerson Y. Factor VII binding to tissue factor in reconstituted phospholipid vesicles: induction of cooperativity by phosphatidylserine. Biochemistry 1986; 25: 4007-4020
• 49 Karp G, Pangasnan R, Hudzik P, Devereux D. Activation of Factor X by a rat sarcoma procoagulant. Clin Res 1991; 39: 451A